Navigation Links
Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Date:10/25/2009

.1%). Discontinuation rates for adverse events were similar in the lorcaserin and placebo groups for Year 1 and Year 2 (7.1% vs. 6.7% and 3.0% vs. 3.0%, respectively).

BLOOM Trial Design

BLOOM, the first of three lorcaserin Phase 3 trials, is a double-blind, randomized, placebo-controlled trial in approximately 100 sites in the US. The trial evaluated 10 mg of lorcaserin dosed twice daily versus placebo over a two-year treatment period in obese patients (BMI 30 to 45) with or without co-morbid conditions and overweight patients (BMI 27 to less than 30) with at least one co-morbid condition. The trial did not include any dose titration or run-in period. Patients were randomized in a 1:1 ratio to lorcaserin or placebo at baseline. At Week 52, 856 patients taking lorcaserin were re-randomized in a 2:1 ratio to continue lorcaserin or to switch to placebo, and 697 patients on placebo were continued on placebo. Patients received echocardiograms at screening, and at 6, 12, 18 and 24 months after initiating dosing in the trial; patients with FDA-defined valvulopathy were excluded from enrolling in the trial.

Phase 3 Program Overview

The lorcaserin Phase 3 program consists of three trials: BLOOM, BLOSSOM and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus). Enrollment in the lorcaserin Phase 3 program is complete with approximately 7,800 patients. Positive results from BLOOM were presented at the 69th Scientific Sessions of the American Diabetes Association in June 2009. BLOOM and BLOSSOM comprise the Phase 3 pivotal registration program and will be the basis for the lorcaserin NDA submission. BLOOM-DM, which is planned as a supplement to the NDA, is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese and overweight patients with type 2 diabetes at about 60 sites in the US.


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. UCLA/RAND study shows that many children of HIV-positive parents are not in their custody
3. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
4. Nutrition model stresses positive experience of eating
5. Ultrasound plus mammography finds more cancers, but increases false positives
6. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
7. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
8. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
9. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
10. A low prevalence of H pylori in HIV-positive patients
11. Drug Company-Funded Asthma Drug Studies More Positive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... 28, 2015 , ... On July 16th NPR reported needle exchange ... proposed bills and laws revolving the implementation of a small pilot program in Miami-Dade ... are continuing to hand out clean needles to drug users who are addicted to ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... Bipolar ... several times a day to a few times a year. The World Health Organization ... study by the National Institute of Mental Health reveals that the United States has ...
(Date:7/28/2015)... ... July 28, 2015 , ... Brookstone®, a nationwide ... to its online product offerings, giving its customers the opportunity to straighten ... technology, SmileCareClub allows patients to get quality, remote invisible aligner treatment from a ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard Scientifics, ... the Company, from time to time and depending on market conditions, to repurchase ... $25 million. Repurchases will be made in open market or privately negotiated transactions ...
(Date:7/28/2015)... ... July 28, 2015 , ... Care ... proprietary, web based clinical knowledge system, called “Referral Guidance.” , Referral ... provides physicians who are anticipating making a subspecialty referral an efficient means to ...
Breaking Medicine News(10 mins):Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2
... Health-care worries hit home, even among the most prosperous, ... survey,published by Consumer Reports reveals a significant disconnect: Americans,overwhelmingly ... have access to quality, affordable health care, and a ... it comes to how,those changes should be adopted, there ...
... Mich.---While our relationships with children and best friends tend to ... see our spouses as irritating and demanding. , ... long-term patterns of relationship negativity among more than 800 adults ... of research showing that marriage and other close relationships enhance ...
... Pa., Feb. 5 West Pharmaceutical,Services, Inc. (NYSE: ... Chairman and Chief Executive Officer, and William Federici, Chief,Financial ... Healthcare,Services Conference at 3:00 p.m. on February 11, 2008 ... corporate presentation document will be posted on the,investor link ...
... June 21-25, ORLANDO, Fla., Feb. 5 ... and Continence Nurses (WOCN) Society Annual,Conference scheduled for ... offers unparalleled educational opportunities for participants,to delve into ... through,workshops and educational sessions, as well as celebrate ...
... WAYNE, Pa., Feb. 5 BioWizard, Inc.,( ... designed for the biomedical research community,announced today that ... (or myBioWizard), a,unique personalization tool available at no ... biomedical researchers access to approximately,half a million new ...
... Quality Reporting for ,Pay ... For ... Allscripts, the,leading provider of clinical software, connectivity and information,solutions ... Clinical Quality Solution (CQS), a powerful new tool that,automates ...
Cached Medicine News:Health News:Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it 2Health News:Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it 3Health News:Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it 4Health News:Seeing our spouses more negatively might be a positive 2Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Registration Now Open for 40th Annual WOCN Conference 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 3Health News:Allscripts Adds TeamPraxis Quality Reporting Software for Electronic Health Records 2Health News:Allscripts Adds TeamPraxis Quality Reporting Software for Electronic Health Records 3Health News:Allscripts Adds TeamPraxis Quality Reporting Software for Electronic Health Records 4
(Date:7/27/2015)... 2015  SeraCare Life Sciences, a leading partner ... the 2015 AACC Annual Meeting today that it ... LLC, a biotechnology company that develops, markets and ... enabled with ViveST™ allow sample collection, transport and ... the terms of the agreement, the two firms ...
(Date:7/27/2015)... July 27, 2015  The fairness of the proposed ... St. Jude Medical ("St. Jude") is the subject of ... shareholder rights law firm.  The investigation is focusing on ... law by the Board of Directors of THOR for ... July 22, 2015, the Company announced it had reached a ...
(Date:7/27/2015)... July 20, 2015 ... the addition of the "Cardiometabolic Drug News ... Afrezza,s discounted pricing is in line with our ... to the product,s commercial appeal. However, contraindications, side ... from gaining a sizeable share of the fast-acting ...
Breaking Medicine Technology:SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 2SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 3WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3
... Oct. 17, 2011 Rochester Medical Implants ( http://www.rmi.us.com ... products, announced today that it has relocated corporate offices ... Indiana. In acknowledgement of the location change, the company ... addresses will be unaffected. The new facility ...
... YORK, Oct. 17, 2011 Reportlinker.com ... report is available in its catalogue: ... - Global Pipeline Analysis, Competitive Landscape ... http://www.reportlinker.com/p0656886/Ophthalmic-Diagnostic-Equipment---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Ophthalmic_Devices ...
Cached Medicine Technology:Rochester Medical Implants Relocates to New Facility in Noblesville, IN 2Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Ophthalmic Diagnostic Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13
... Blades are designed for the retraction ... basal lesions. Reduced obstruction when working ... instrument, range of blade sizes from ... Quick change and release, malleable material ...
Permanently sharp, slightly angulated blade, delicate sharp dissection, excellent balanced, ergonomic design....
Epstein Curettes 3.0 mm, length 8" (203 mm)....
Codman-Cone Ring Curettes, ring diameter (I.D.) 5 / 16" (8 mm), total length 9" (229 mm)....
Medicine Products: